Ghost Tree Capital’s Cymabay Therapeutics CBAY Stock Holding History

Ghost Tree Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-90,000	Closed	-$2.13M	–	83
2023 Q4	$2.13M	Buy	+90,000	New	+$1.6M	0.7%	42
2019 Q4	–	Sell	-440,000	Closed	-$2.25M	–	62
2019 Q3	$2.25M	Sell	440,000 -560,000	-56%	-$3.39M	0.57%	39
2019 Q2	$7.16M	Buy	1,000,000 +250,000	+33%	+$2.83M	1.49%	18
2019 Q1	$9.96M	Buy	+750,000	New	+$7.98M	2.6%	16
2017 Q3	–	Sell	-650,000	Closed	-$3.74M	–	77
2017 Q2	$3.74M	Buy	650,000 +150,000	+30%	+$639K	0.78%	48
2017 Q1	$2.15M	Buy	+500,000	New	+$1.43M	0.4%	54
2015 Q4	–	Sell	-400,000	Closed	-$776K	–	72
2015 Q3	$776K	Buy	+400,000	New	+$1.09M	0.35%	61

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ghost Tree Capital's CBAY Position: Q1 2024 in Review

Ghost Tree Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 90,000 shares — an estimated $2.13M sold.

Ghost Tree Capital first reported a position in CBAY in Q3 2015 and held it in 7 quarters. The position peaked at $9.96M in Q1 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Ghost Tree Capital reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Ghost Tree Capital sold 90,000 Cymabay Therapeutics shares in Q1 2024, an estimated $2.13M.
Ghost Tree Capital first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 7 quarters.
Ghost Tree Capital's Cymabay Therapeutics position peaked at $9.96M in Q1 2019.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Ghost Tree Capital's 13F filing for Q1 2024, filed 15 May 2024.